MPP signs on four generics makers to make Novartis’ Tasigna more accessible

The Med­i­cines Patent Pool has set up sub­li­cense agree­ments with four man­u­fac­tur­ers to pro­duce gener­ic ver­sions of No­var­tis’ can­cer drug Tasigna, as part of an on­go­ing ef­fort to make ac­cess to med­i­cines more eq­ui­table.

The UN-backed agency an­nounced the news Thurs­day, say­ing that In­di­an gener­ics mak­ers Eu­gia, Het­ero and Dr. Red­dy’s Lab­o­ra­to­ries — along with In­done­sia com­pa­ny Bright­Gene — can man­u­fac­ture and sup­ply gener­ic ver­sions of nilo­tinib, which was first ap­proved by the FDA to treat chron­ic myeloid leukemia in 2007.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN